Amicus Therapeutics ($FOLD) announced receiving the Australian Therapeutic Goods Administration approval for oral Galafold (migalastat) for the long-term treatment of patients at least 16 years old with Fabry disease who have an amenable mutation.
Alexion Pharmaceuticals ($ALXN) announced receiving three new patents No. 9,732,149, No. 9,718,880 and No. 9,725,504 from the USPTO. These patents cover the composition of matter of eculizumab (Soliris), pharmaceutical formulations of eculizumab and methods of treating paroxysmal nocturnal hemoglobinuria (PNH) with eculizumab, respectively. The patent protection will remain effective until 2027.